Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Dimethylfumarate Impairs Neutrophil Functions.
Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis.
Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.
Episode 26 with Dr. Tim Kennedy on remyelination and oligodendrocyte development
Primary results of DECIDE: a randomized, double-blind, double-dummy, active-controlled trial of daclizumab HYP vs. Interferon β-1a in RRMS patients
Therapeutic effects of systemic administration of chaperone αB-crystallin associated with binding proinflammatory plasma proteins.
Gene Expression Profiles of Autophagy-Related Genes in Multiple Sclerosis.
Episode 16 with Dr. Revere [double-quote]Rip[double-quote] Kinkel on how to improve patient outreach
Firategrast
Serum IL-33 levels and skin mRNA expression in Behçet's disease.
The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis.
Dimethylfumarate inhibits tumor-necrosis-factor-induced CD62E expression in an NF-kappa B-dependent manner.
Multiple sclerosis: pathogenesis and treatment.
Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial.
Regulation of brain endothelial barrier function by microRNAs in health and neuroinflammation.
The differential diagnosis of neurological diseases by fractionating electrophoretically the CSF gamma-globulins.
Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients.
Consensus statement on the treatment of multiple sclerosis by the Spanish Society of Neurology in 2016.
17 beta-estradiol inhibits cytokine, chemokine, and chemokine receptor mRNA expression in the central nervous system of female mice with experimental autoimmune encephalomyelitis.
Interrater Reliability of Four Sensory Measures in People with Multiple Sclerosis.
Episode 32 with Dr. David Holtzman on the connection between MS and Alzheimer 's disease
Masitinib in Patients with Primary Progressive Multiple Sclerosis (PPMS) or Relapse-Free Secondary Multiple Sclerosis (SPMS)
Multiple sclerosis prevalence in the United States commercially insured population.
Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
Pharmacokinetics and metabolism of mitoxantrone. A review.

Pages